Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients

International Journal of Neuropsychopharmacology

Volumn 14, Issue 3, 2011, Pages 399-404

  Laske, Christoph ^a   Stellos, Konstantinos ^a   Hoffmann, Nadine ^a   Stransky, Elke ^a   Straten, Guido ^a   Eschweiler, Gerhard W ^a   Leyhe, Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Alzheimer's disease; BDNF; cognitive decline; neuroprotection; prognostic marker

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; FEMALE; FOLLOW UP; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; TIME FACTORS;

EID: 79960343573     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001008     Document Type: Article

References (30)

1. Angelucci F, Spalletta G, di Iulio F, Ciaramella A, et al. (2010). Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels. Current Alzheimer Research 7, 15-20
2. Arancibia S, Silhol M, Moulière F, Meffre J, et al. (2008). Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiology of Disease 31, 316-326
3. Bekinschtein P, Cammarota M, Katche C, Slipczuk L, et al. (2008). BDNF is essential to promote persistence of long-term memory storage. Proceedings of the National Academy of Sciences USA 105, 2711-2716 (Pubitemid 351520578)
4. Chuang DM, Manji HK (2007). In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biological Psychiatry 62, 4-6 (Pubitemid 46898231)
5. Doody RS, Massman P, Dunn JK (2001). A method for estimating progression rates in Alzheimer disease. Archives of Neurology 58, 449-454 (Pubitemid 32217462)
6. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-Mental- State'. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198
7. Foulstone EJ, Tavaré JM, Gunn-Moore FJ (1999). Sustained phosphorylation and activation of protein kinase B correlates with brain-derived neurotrophic factor and insulin stimulated survival of cerebellar granule cells. Neuroscience Letters 264, 125-128 (Pubitemid 29195965)
8. Fujimura H, Altar CA, Chen R, Nakamura T, et al. (2002). Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thrombosis and Haemostasis 87, 728-734 (Pubitemid 34302963)
9. Gunstad J, Benitez A, Smith J, Glickman E, et al. (2008). Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. Journal of Geriatric Psychiatry and Neurology 21, 166-170
10. Komulainen P, Pedersen M, Hanninen T, Bruunsgaard H, et al. (2008). BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiology of Learning and Memory 90, 596-603
11. Kraemer HC, Tinklenberg J, Yesavage JA (1994). 'How far' vs. 'how fast' in Alzheimer's disease. The question revisited. Archives of Neurology 51, 275-279
12. Laske C, Stransky E, Leyhe T, Eschweiler GW, et al. (2006). Stage-dependent BDNF serum concentrations in Alzheimer's disease. Journal of Neural Transmission 113, 1217-1224 (Pubitemid 44291016)
13. Laske C, Stransky E, Leyhe T, Eschweiler GW, et al. (2007). BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. Journal of Psychiatric Research 41, 387-394 (Pubitemid 46187251)
14. Leroy K, Boutajangout A, Authelet M, Woodgett JR, et al. (2002). The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathologica 103, 91-99 (Pubitemid 36067485)
15. Leyhe T, Eschweiler GW, Stransky E, Gasser T, et al. (2009). Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. Journal of Alzheimer's Disease 16, 649-656
16. Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, et al. (2008). Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience 258, 124-128 (Pubitemid 351441932)
17. Li G, Peskind ER, Millard SP, Chi P, et al. (2009). Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in nondemented subjects. PLoS ONE 4, e5424
18. Marmigere F, Choby C, Rage F, Richard S, et al. 2001 Rapid stimulatory effects of brain-derived neurotrophic factor and neurotrophin-3 on somatostatin release and intracellular calcium rise in primary hypothalamic cell cultures. Neuroendocrinology 74 43-54. (Pubitemid 32642078)
19. Mattson MP,Maudsley S, Martin B (2004). BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences 27, 589-594 (Pubitemid 39221394)
20. McKhann G, Drachman D, Folstein M, Katzman R, et al. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 30-44
21. Nagahara AH, Merrill DA, Coppola G, Tsukada S, et al. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nature Medicine 15, 331-337
22. Noh MY, Koh SH, Kim Y, Kim HY, et al. (2009). Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. Journal of Neurochemistry 108, 1116-1125
23. O'Bryant SE, Hobson V, Hall JR, Waring SC, et al. (2009). Brain-derived neurotrophic factor levels in Alzheimer's disease. Journal of Alzheimer's Disease 17, 337-341
24. Pan W, Banks WA, Fasold MB, Bluth J, et al. (1998). Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553-1561 (Pubitemid 28550429)
25. Poduslo JF, Curran GL (1996). Permeability at the bloodbrain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Research. Molecular Brain Research 36, 280-286
26. Soto ME, Andrieu S, Cantet C, Reynish E, et al. (2008). Predictive value of rapid decline in mini mental state examination in clinical practice for prognosis in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 26, 109-116
27. Teri L, McCurry SM, Edland SD, Kukull WA, et al. (1995). Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. Journal of Gerontology, A: Biological Sciences and Medical Sciences 50A, M49-M55
28. Villuendas G, Sánchez-Franco F, Palacios N, Fernández M, et al. (2001). Involvement of VIP on BDNF-induced somatostatin gene expression in cultured fetal rat cerebral cortical cells. Brain Research Molecular Brain Research 19, 59-66 (Pubitemid 32964746)
29. Yasutake C, Kuroda K, Yanagawa T, Okamura T, et al. (2006). Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. European Archives of Psychiatry and Clinical Neurosciences 256, 402-406 (Pubitemid 44584054)
30. Yu H, Zhang Z, Shi Y, Bai F, et al. (2008). Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. Journal of Clinical Psychiatry 69, 1104-1111 (Pubitemid 352031594)